A61P 17 - Drugs for dermatological disorders

Patents for A61P 17 - Drugs for dermatological disorders (106,455)
10/2001
10/25/2001	WO2001079173A2 Enamine derivatives as cell adhesion molecules
10/25/2001	WO2001079166A1 Vitamin d derivatives
10/25/2001	WO2001079164A2 N-substituted dithiocarbamates for the treatment of biological disorders
10/25/2001	WO2001079156A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	WO2001078768A2 Targeted vaccine delivery systems
10/25/2001	WO2001078754A2 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
10/25/2001	WO2001078733A1 Alpha,beta-unsaturated sulfones for treating proliferative disorders
10/25/2001	WO2001078730A1 Methods and compositions useful in enhancing oxygen delivery to cells
10/25/2001	WO2001078723A1 Compounds and methods
10/25/2001	WO2001078719A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	WO2001078712A1 Substituted styryl benzylsulfones for treating proliferative disorders
10/25/2001	WO2001078692A2 Membrane delivery system
10/25/2001	WO2001078677A1 Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials
10/25/2001	WO2001078675A1 Use of natural substances in the production of cosmetic preparations
10/25/2001	WO2001078674A1 A composition based on natural extracts useful in the prevention and treatment of cutaneous wrinkles
10/25/2001	WO2001078662A1 Hair growth stimulant compositions with sustained action
10/25/2001	WO2001078654A2 Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	WO2001078533A2 Nutritional modules
10/25/2001	WO2001072262A3 New cosmetic, personal care, cleaning agent, and nutritional supplement compositions comprising bioactive glass and methods of making and using the same
10/25/2001	WO2001044246A8 Bicyclic inhibitors of glycogen synthase kinase 3
10/25/2001	WO2001041778B1 Melanin synthesis inhibition compound and composition containing the same
10/25/2001	WO2001027113A3 PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES
10/25/2001	WO2001025238A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases
10/25/2001	WO2001021605A3 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food
10/25/2001	WO2001012790A3 Isomerase proteins
10/25/2001	WO2000062788A9 Treatment of hypersensitivity reaction disorders
10/25/2001	WO2000061541A8 Pharmaceutical compounds
10/25/2001	WO2000048554A9 Synergistic antimicrobial skin washing compositions
10/25/2001	US20010034362 Pyrrolidine derivatives for vision and memory disorders
10/25/2001	US20010034354 Antiulcer agents
10/25/2001	US20010034340 Hormone replacement therapy
10/25/2001	US20010034337 Antiproliferative agents
10/25/2001	US20010034051 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes
10/25/2001	US20010033848 Adjustment of cellular nicotinamide-adenine dinucleotide
10/25/2001	US20010033847 Triglyceride
10/25/2001	DE10020517A1 New 13-halo or cyano-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
10/25/2001	CA2747325A1 Albumin fusion proteins
10/25/2001	CA2407531A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
10/25/2001	CA2406403A1 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof
10/25/2001	CA2406378A1 Targeted vaccine delivery systems
10/25/2001	CA2406245A1 Il-174 uses, compositions and methods
10/25/2001	CA2406192A1 Therapeutic compounds and methods for formulating v3, a versican isoform
10/25/2001	CA2405709A1 Albumin fusion proteins
10/25/2001	CA2405701A1 Albumin fusion proteins
10/25/2001	CA2405696A1 5-substituted tetralones as inhibitors of ras farnesyl transferase
10/25/2001	CA2405597A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	CA2405563A1 Albumin fusion proteins
10/25/2001	CA2405557A1 Albumin fusion proteins
10/25/2001	CA2405550A1 Albumin fusion proteins
10/25/2001	CA2405525A1 Albumin fusion proteins
10/25/2001	CA2405451A1 Molecules associated with human reproduction
10/25/2001	CA2405385A1 Hair growth stimulant compositions with sustained action
10/25/2001	CA2405377A1 Nutritional modules
10/25/2001	CA2403508A1 Extracellular matrix polynucleotides, polypeptides, and antibodies
10/25/2001	CA2403490A1 N-substituted dithiocarbamates for the treatment of biological disorders
10/24/2001	EP1148054A1 Thyroid receptor ligands
10/24/2001	EP1147776A2 Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
10/24/2001	EP1147775A2 Use of botulinum toxin type B for the manufacture of a medicament for reducing pain associated with a muscle disorder
10/24/2001	EP1147765A1 New active, compositions containing it and it's use in cosmetic, dermocosmetic, dermopharmacy or pharmacy, on woven or nonwoven fabrics
10/24/2001	EP1147214A1 A novel method for designing protein kinase inhibitors
10/24/2001	EP1147193A1 Platelet-derived growth factor/vascular endothelial growth factor-like growth factor h, and uses thereof
10/24/2001	EP1147175A2 Fibres for culturing eukaryotic cells
10/24/2001	EP1147167A1 Method for obtaining an oil that is rich in hydroxyoctadecadienoic fatty acids (hode) or the esters thereof from a mixture containing linoleic acid or the esters thereof
10/24/2001	EP1147121A2 Ketolide antibiotics
10/24/2001	EP1147119A1 2,3-o-isoproylidene derivatives of monosaccharides as cell adhesion inhibitors
10/24/2001	EP1147107A1 Novel angiogenesis inhibitors
10/24/2001	EP1147104A1 Aromatic heterocyclic compounds as antiinflammatory agents
10/24/2001	EP1147102A2 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1147101A1 Reverse hydroxamate inhibitors of matrix metalloproteinases
10/24/2001	EP1147097A1 Peptidyl heterocyclic ketones useful as tryptase inhibitors
10/24/2001	EP1147095A1 2, 3, 4, 5-tetrahydro-1h-[1, 4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
10/24/2001	EP1147091A2 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
10/24/2001	EP1147089A1 Phenylphenanthridines with pde-iv inhibiting activity
10/24/2001	EP1147088A1 6-arylphenanthridines with pde-iv inhibiting activity
10/24/2001	EP1147086A1 Compositions for the treatment of skin diseases
10/24/2001	EP1147078A1 Acetylenic (beta)-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1146908A1 Formulations comprising antisense nucleotides to connexins
10/24/2001	EP1146889A2 Identification of specific differentially expressed mycobacterial antigens
10/24/2001	EP1146886A1 Soya extract containing lipids, process for its production, and pharmaceutical and cosmetic composition
10/24/2001	EP1146885A1 Pre-conditioning against cell death
10/24/2001	EP1146883A1 Modulation of immune response by ribavirin
10/24/2001	EP1146875A1 Myt1 kinase inhibitors
10/24/2001	EP1146874A1 Vitronectin receptor antagonist
10/24/2001	EP1146873A1 Anti-androgens and methods for treating disease
10/24/2001	EP1146868A1 Anti-inflammatory agents
10/24/2001	EP1146866A1 A method for treating patients with acne by administering a cyclic gmp pde inhibitor
10/24/2001	EP1146851A1 Galenic formulation containing biotin
10/24/2001	EP1146850A1 Use of a plant extract of the genus rosmarinus in compositions for treating ageing skin symptoms
10/24/2001	EP1146844A1 Membrane lipid compositions
10/24/2001	EP1146790A1 Compounds and methods
10/24/2001	EP1035824A4 A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
10/24/2001	EP0921791B1 Composition comprising mupirocin and chlorhexidine
10/24/2001	EP0869955B1 N-acyl-2-substituted-4-(benzimidazolyl- or imidazopyridinyl-substituted residues)-piperidines as tachykinin antagonists
10/24/2001	EP0809657B1 Process for producing chitosan-glucan complexes, compounds producible therefrom and their use
10/24/2001	CN1319139A Polynucleotide constructs and uses thereof
10/24/2001	CN1319133A Short peptides which selectively modulate activity of protein kinases
10/24/2001	CN1319097A Benzoxazine and benzothiazine derivatives and their use in medicines
10/24/2001	CN1319096A Quinazoline derivatives and pharmaceutical applications thereof
10/24/2001	CN1319094A Imidazolyl derivatives
10/24/2001	CN1319093A Aminoalkyl-3,4-dihydroquindine derivates as No-synthase inhibitors

1 ... 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 ... 1065